Stockscreener 앱 받기
2.20
2.22%
-0.05
시간 외 거래:
2.21
0.010
+0.45%
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Iovance Biotherapeutics Stock: Analyzing Its Surprising Surge - StocksToTrade
Will Iovance Biotherapeutics’ Stock Surge? - timothysykes.com
Iovance Biotherapeutics: A Surge or A Signal to Watch? - timothysykes.com
Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance
Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Yahoo Finance
With Iovance Biotherapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - Finviz
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Stock Analysis & Fast Momentum Stock Entry Tips - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock benefits from AI revolutionJuly 2025 PostEarnings & Safe Capital Investment Plans - Newser
What technical charts say about Iovance Biotherapeutics Inc. stock2025 Price Action Summary & Reliable Entry Point Trade Alerts - Newser
Will Iovance Biotherapeutics Inc. stock recover faster than peersWeekly Stock Summary & Verified Entry Point Signals - Newser
How buyback programs support Iovance Biotherapeutics Inc. (2LB) stockInsider Selling & Free Verified High Yield Trade Plans - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock is upgraded to buyMarket Activity Recap & Daily Technical Forecast Reports - Newser
What dividend safety rating applies to Iovance Biotherapeutics Inc. (2LB) stock2025 Earnings Surprises & Weekly Return Optimization Alerts - Newser
Cash per share of Iovance Biotherapeutics Inc – DUS:2LB - TradingView
Why Iovance Biotherapeutics Inc. (2LB) stock is listed among top recommendationsChart Signals & Community Trade Idea Sharing Platform - Newser
Is Iovance Biotherapeutics Inc. (2LB) stock ideal for retirement investors2025 Fundamental Recap & Precise Trade Entry Recommendations - Newser
Officer Graf Finckenstein Acquires 6,247 Of Iovance Biotherapeutics Inc [IOVA] - TradingView
Officer Puri Acquires 3,002 Of Iovance Biotherapeutics Inc [IOVA] - TradingView
Iovance Biotherapeutics (NASDAQ: IOVA) officer reports RSU vesting and tax withholding on Form 4 - Stock Titan
Why Iovance Biotherapeutics Inc. stock remains undervaluedJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - Newser
Iovance Biotherapeutics Stock Hits Day Low of $2 Amid Price Pressure - Markets Mojo
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.9%What's Next? - MarketBeat
FINAL REMINDER IOVA DEADLINE: Bronstein, Gewirtz & Grossman LLC A - The National Law Review
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA)Join by July 14, 2025Contact Levi & Korsinsky - The National Law Review
Iovance Biotherapeutics Stock Dips Amid Market Reactions - StocksToTrade
Virtus Investment Advisers LLC Increases Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc - The National Law Review
IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Iovance Biotherapeutics, Inc. (IOVA) Class Action Lawsuit: Levi - The National Law Review
Kennondale Capital Management LLC Invests $384,000 in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Iovance’s Tumultuous Journey: Positive Drug Trials Amidst Financial Turbulence - StocksToTrade
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA) - Seeking Alpha
Barclays Boosts IOVA Price Target to $9, Maintains Overweight Ra - GuruFocus
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Is Iovance Biotherapeutics Inc. stock gaining market shareWall Street Watch & Risk Managed Investment Signals - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock remains stable2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock gets analyst attentionJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
What technical patterns form on Iovance Biotherapeutics Inc. (2LB) stock charts - newser.com
How Iovance Biotherapeutics Inc. (2LB) stock compares with market leadersMarket Movement Recap & AI Based Buy and Sell Signals - newser.com
Quantitative breakdown of Iovance Biotherapeutics Inc. recent moveGlobal Markets & High Accuracy Swing Entry Alerts - newser.com
Strategies to average down on Iovance Biotherapeutics Inc.Portfolio Growth Summary & Stepwise Trade Execution Plans - newser.com
1.08%
0.91%
자본화:
|
볼륨(24시간):